US05465P1012 - Common Stock
AXONICS INC
NASDAQ:AXNX (3/28/2024, 1:38:50 PM)
68.95
+0.05 (+0.07%)
Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 610 full-time employees. The company went IPO on 2018-10-31. The company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10 cubic centimeters (cc) in volume, utilizes constant current stimulation, a recharge-free patient remote control and offers broad magnetic resonance imaging (MRI) access. Its SNM systems include an easy-to-use wireless patient remote control that does not require recharging or replacement batteries. The company also offers a clinician programmer that guides the implanting physician through lead placement and stimulation programming.
AXONICS INC
26 Technology Drive
Irvine CALIFORNIA 92618
P: 19493966322
CEO: Raymond W. Cohen
Employees: 610
Website: https://www.axonics.com/
Boston Scientific Corp.’s proposed $3.7 billion acquisition of medical device maker Axonics Inc. will likely be scrutinized by the US Federal Trade Commission because the companies are the dominant providers of some treatments for urinary incontinence, according to antitrust experts.
Medtronic (MDT) has filed a complaint with the US International Trade Commission and a U.S. District Court accusing Axonics (AXNX) of patent infringement. Read more here.
Here you can normally see the latest stock twits on AXNX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: